Ortataxel
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| (3aS,4R,7R,8aS,9S,10aR,12aS,13S,13aS)-7,12a-bis(acetyloxy)-4-({(2R,3S)-3-[tert-butoxycarbonyl)amino]-2-hydroxy-5-methylhexanoyl}oxy)-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-6,13a-methano[1,3]dioxolo[8,9]cyclodeca[1,2-d][1]benzoxet-13-yl benzoate | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 186348-23-2 |
| ATC code | None |
| PubChem | CID 10557575 |
| UNII | 8H61Y4E29N  |
| Chemical data | |
| Formula | C44H57NO17 |
| Mol. mass | 871.92 g/mol |
 (what is this?) (verify) |
|
Ortataxel is a drug used in chemotherapy. As of June 2009[update], Spectrum Pharmaceuticals has the drug is in a Phase 2 clinical trial.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
